Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management

References

• Ehringer H, Hornykiewcz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behaviour in diseases of the extrapyramidal system. Klin. Wochenschr.38, 1236–1239 (1960).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O. Early rasagiline treatment slows UPDRS decline in the ADAGIO delayed start study. Ann. Neurol.64(Suppl. 12), S68 (2008). (Abstract WIP-11).
   Google Scholar
• Agid Y, Ahlshog E, Albanese A et al. Levodopa in the treatment of Parkinson’s disease: a consensus meeting. Mov. Disord.14, 911–913 (1995).
   Google Scholar
• Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet359(9317), 1589–1598 (2002).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Holford NHG. The response to levodopa in Parkinson’s disease: imposing pharmacological law and order. Ann. Neurol.39, 561–573 (1996).
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov. Disord.22(10), 1379–1389 (2007).
   PubMed Web of Science ®Google Scholar
• Obeso JA, Grandas F, Vaamonde J et al. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology.39(Suppl. 2), 11–19 (1989).
   PubMed Web of Science ®Google Scholar
• Marsden CD, Parkes JD, Quinn N. Fluctuations disability in Parkinson’s diseaseclinical aspects. In: Movement Disorders. Masden CD, Fahn S (Eds). Butterworth, London, UK 96–122 (1982).
   Google Scholar
• Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov. Disord.20(2), 224–230 (2005).
   PubMed Web of Science ®Google Scholar
• Poewe W. Non-motor symptoms in Parkinson’s disease. Eur. J. Neurol.15(Suppl. 1), 14–20 (2008).
   PubMed Web of Science ®Google Scholar
• Olanow CW. The pathogenesis of cell death in Parkinson’s disease – 2007. Mov. Disord.22(Suppl. 17), S335–S342 (2007).
   PubMed Web of Science ®Google Scholar
• Gandhi S, Wood NW. Molecular pathogenesis of Parkinson’s disease. Hum. Mol. Genet.14(Spec No. 2), 2749–2755 (2005).
   Web of Science ®Google Scholar
• Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat. Disord.8(2), 95–100 (2001).
   PubMed Web of Science ®Google Scholar
• Stowe RL, Ives NJ, Clarke C et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst. Rev.2, CD006564 (2008).
   Google Scholar
• Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier versus later l-DOPA. Arch. Neurol.56, 529–535 (1999).
   PubMed Web of Science ®Google Scholar
• Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology62(1 Suppl. 1), S47–S55 (2004).
   PubMed Web of Science ®Google Scholar
• Calabresi P, Di Filippo M, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov. Disord.23(Suppl. 3), S570–S579 (2008).
   PubMed Web of Science ®Google Scholar
• Kurlan R, Rothfield KP, Woodward WR et al. Erratic gastric emptying may cause “random” fluctuations of parkinsonian mobility. Neurology38, 419–421 (1988).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The “on–off” phenomenon in Parkinson’s disease: relation to levodopa absorption and transport. N. Engl. J. Med.310, 483–488 (1984).
   PubMed Web of Science ®Google Scholar
• Tsui JK, Ross S, Poulin K et al. The effect of dietary protein on the efficacy of levodopa: a double blind study. Neurology39, 549–552 (1989).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat. Clin. Pract. Neurol.2(7), 382–392 (2006).
   PubMedGoogle Scholar
• Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov. Disord.23(Suppl. 3), S599–S5612 (2008).
   PubMed Web of Science ®Google Scholar
• Maratos EC, Jackson MJ, Pearce RK, Jenner P. Antiparkinsonian activity and dyskinesia risk of ropinirole and l-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus). Mov. Disord.16(4), 631–641 (2001).
   PubMed Web of Science ®Google Scholar
• Pearce RK, Heikkilä M, Lindén IB, Jenner P. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology156(4), 402–409 (2001).
   PubMedGoogle Scholar
• Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov. Disord.8(5), 487–495 (2003).
   Google Scholar
• Smith LA, Jackson MJ, Al-Barghouthy Get al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Disord.20(3), 306–314 (2005).
   PubMed Web of Science ®Google Scholar
• Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad. Med. J.83(980), 384–388 (2007).
   PubMed Web of Science ®Google Scholar
• Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox. Res.5(1–2), 139–146 (2003).
   PubMed Web of Science ®Google Scholar
• Calon F, Morissette M, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa induced motor complications. Mov. Disord.18(3), 241–253 (2003).
   PubMedGoogle Scholar
• Santini E, Valjent E, Fisone G. Parkinson’s disease: levodopa-induced dyskinesia and signal transduction. FEBS. J.275(7), 1392–1399 (2008).
   PubMed Web of Science ®Google Scholar
• Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord.20, 919–931 (2005).
   PubMed Web of Science ®Google Scholar
• Obeso JA, Rodriguez-Oroz MC, Marin C et al. The origin of motor fluctuations in Parkinson’s disease: importance of dopaminergic innervations and basal ganglia circuits. Neurology62(Suppl. 1), S17–S30 (2004).
   PubMed Web of Science ®Google Scholar
• Wolters E, Lees AJ, Volkmann J, van Laar T, Hovestadt A. Managing Parkinson’s disease with continuous dopaminergic stimulation. CNS Spectr.13(4 Suppl. 7), 1–14 (2008).
   Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol.5, 677–687 (2006).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology62(Suppl. 1), S56–S63 (2004).
   PubMed Web of Science ®Google Scholar
• Wolters ECh. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson’s disease. Parkinsonism Relat. Disord.13(Suppl.), S18–S23 (2007).
   PubMed Web of Science ®Google Scholar
• Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ. A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease. J. Neurol.251(11), 1370–1374 (2004)
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Hughes A, Evans A et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov. Disord.20(2), 151–157 (2005).
   PubMed Web of Science ®Google Scholar
• Manson AJ, Hanagasi H, Turner K et al. Intravenous apomorphine therapy in Parkinson’s disease: clinical and pharmacokinetic observations. Brain124(2), 331–340 (2001).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Carter JH. Apomorphine can sustain the long-duration response to l-DOPA in fluctuating PD. Neurology54(1), 247–250 (2000).
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease. Drugs Aging21(11), 687–709 (2004).
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF, Gutmann L, Hull KL Jr, Bottini PB, Sherry JH; APO302 Study Investigators. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat. Disord.13(2), 93–100 (2007).
   PubMed Web of Science ®Google Scholar
• Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. Apomorphine responses in Parkinson’s disease and the pathogenesis of motor complications. Neurology50(2), 573–574 (1998).
   PubMedGoogle Scholar
• Trosch RM, Silver D, Bottini PB. Intermittent subcutaneous apomorphine therapy for ‘off’ episodes in Parkinson’s disease: a 6-month open-label study. CNS Drugs22(6), 519–527 (2008).
   PubMed Web of Science ®Google Scholar
• Lewitt PA, Ondo WG, Van Lunen B, Bottini PB. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating “off” episodes in advanced Parkinson disease. Clin. Neuropharmacol. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• De Gaspari D, Siri C, Landi A et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry77(4), 450–453 (2006).
   PubMed Web of Science ®Google Scholar
• Alegret M, Valldeoriola F, Martí Met al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson’s disease. Mov. Disord.19(12), 1463–1469 (2004).
   PubMed Web of Science ®Google Scholar
• Morgante L, Basile G, Epifanio A et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson’s disease: a follow-up of two years. Arch. Gerontol. Geriatr. Suppl.9, 291–296 (2004).
   PubMedGoogle Scholar
• Weaver FM, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA301(1), 63–73 (2009).
   PubMed Web of Science ®Google Scholar
• Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology25(12), 1144–1148 (1975).
   PubMed Web of Science ®Google Scholar
• Hardie RJ, Lees AJ, Stern GM. On–off fluctuations in Parkinson’s disease. A clinical and neuropharmacological study. Brain107(2), 487–506 (1984).
   PubMed Web of Science ®Google Scholar
• Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev. Neurother.6(10), 1403–1411 (2006).
   PubMedGoogle Scholar
• Kurlan R, Nutt JG, Woodward WR et al. Duodenal and gastric delivery of levodopa in parkinsonism. Ann. Neurol.23(6), 589–595 (1988).
   PubMed Web of Science ®Google Scholar
• Sage JI, Sonsalla PK, McHale DM, Heikkila RE, Duvoisin RC. Clinical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson’s disease. Adv. Neurol.53, 383–386 (1990).
   PubMedGoogle Scholar
• Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson’s disease. Expert Opin. Pharmacother.8, 657–664 (2007).
   PubMed Web of Science ®Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology64(2), 216–223 (2005).
   PubMed Web of Science ®Google Scholar
• Antonini A. New strategies in motor parkinsonism. Parkinsonism Relat. Disord.13(Suppl. 3), S446–S449 (2007).
   PubMedGoogle Scholar
• Antonini A. Continuous dopaminergic stimulation – from theory to clinical practice. Parkinsonism Relat. Disord.13(Suppl.), S24–S28 (2007).
   PubMed Web of Science ®Google Scholar
• Antonini A, Mancini F, Canesi M et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease. Neurodegener. Dis.5(3-4), 244–246 (2008).
   PubMed Web of Science ®Google Scholar
• Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov. Disord.20(2), 224–230 (2005).
   PubMed Web of Science ®Google Scholar
• Lee MA, Walker RW, Hildreth AJ, Prentice WM. Individualized assessment of quality of life in idiopathic Parkinson’s disease. Mov. Disord.21(11), 1929–1934 (2006).
   PubMedGoogle Scholar
• Antonini A, Isaias IU, Canesi M et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov. Disord.22(8), 1145–1149 (2007).
   PubMed Web of Science ®Google Scholar
• Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease – long-term experience. Acta Neurol. Scand.104(6), 343–348 (2001).
   PubMed Web of Science ®Google Scholar
• Krack Paul, Batir A, Van Blercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N. Engl. J. Med.349, 1925–1934 (2003).
   PubMed Web of Science ®Google Scholar
• Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidusin Parkinson’s disease. N. Engl. J. Med.345, 956–963 (2001).
   PubMed Web of Science ®Google Scholar
• Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol.8(1), 67–81 (2009).
   PubMed Web of Science ®Google Scholar
• Cilia R, Marotta G, Landi A et al. Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson’s disease: a prospective case–control study. Clin. Neurol. Neurosurg.111(2), 140–146 (2009).
   PubMedGoogle Scholar
• Pahwa R, Factor SA, Lyons KE et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66(7), 983–995 (2006).
   PubMed Web of Science ®Google Scholar
• Lang AE, Houeto JL, Krack P et al. Deep brain stimulation: preoperative issues. Mov. Disord.21(Suppl. 14), S171–S196 (2006).
   PubMed Web of Science ®Google Scholar
• Ory-Magne F, Brefel-Courbon C, Simonetta-Moreau M et al. Does ageing influence deep brain stimulation outcomes in Parkinson’s disease? Mov. Disord.22(10), 1457–1463 (2007).
   PubMedGoogle Scholar
• Weaver FM, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA301(1), 63–73 (2009).
   PubMed Web of Science ®Google Scholar
• Witt K, Daniels C, Reiff J et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol.7(7), 605–614 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Oroz MC, Obeso JA, Lang AE et al. Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain128(10), 2240–2249 (2005).
   PubMed Web of Science ®Google Scholar
• Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations. Acta Neurol. Scand.119(5), 345–348 (2008).
   PubMedGoogle Scholar